Table of Contents
Contracts & Grants
Information is courtesy of the Office of Sponsored Projects. Each listing includes the faculty member's name and school(s) appointments at The University of Texas Health Science Center at Houston, contracting or granting agency, funding amount and project title.
Jaroslaw Aronowski, Medical School (MS) and Graduate School of Biomedical Sciences (GSBS), Dompe Pharmaceuticals, $101,004, Sponsored Laboratory Testing Agreement.
Marlene Z. Cohen, School of Nursing (SON), UT M. D. Anderson Cancer Center, $18,505, Methylphenidate for Fatigue in Advanced Cancer Patients.
Lisa De Ybarrondo, MS, National Environmental Education and Training Foundation, $9,000, Integrating Environmental Management of Pediatric Asthma into Health Care: Creating Faculty Champions at Medical Schools and Outreach to the Health Care Community.
Mazen M. Dimachkie, MS, Texas Heart Institute, $62,920, A Phase I-II Randomized Comparison of Autologous Bone Marrow Derived Aldehyde Dehydrogens-Bright (ALDH) Enriched Mononuclear Cells Randomized against Unfractionated Autologous Mononuclear Bone Marrow in Patients with Rutherford 4 or 5 Peripheral Arterial Occlusive Disease.
Anne H. Dougherty, MS, Medtronic Inc., $2,700, Is AF Ablation Ready for Prime Time?
Valentin Dragoi, MS and GSBS, National Institutes of Health (NIH), $1,304,307, Dynamic Coding of Image Features in Primary Visual Cortex.
Kevin W. Finkel, MS, Biosite Incorporated, $67,275, Evaluation of NGAL in Early and Evolving Acute Kidney Injury (EVOLVE).
Lorraine Q. Frazier, SON, American Nurses Foundation, $15,000, Promoting the Cardiovascular and Mental Health of Economically Disadvantaged Women Hospitalized for Acute Coronary Symptoms.
James C. Grotta, MS, University of California, San Diego, $40,000, ICTuS-L, Phase 1 Study of Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke.
Adelaide A. Hebert, MS, Amgen Inc., $81,404, Observational Post-Marketing Safety Surveillance Registry of ENBREL (Etanercept) for the Treatment of Psoriasis.
Jacqueline T. Hecht, MS and GSBS, Shriners Hospital for Crippled Children, $13,980, Thrombospondins and other Matricellular Proteins in Tissue Organization and Homeostasis.
Keith Hoots, MS and GSBS, Bayer Corporation, $17,112, Cultural and Psychometric Validation of the HAEMO-QoL into American English; and Wyeth Pharmaceuticals, $19,126, A Multi-Center, Open-Label Study to Compare On-Demand Treatment with 2 Prophylaxis Regimens of Recombinant Coagulation Factor IX (BeneFIX) Reformulated Drug Product (rFIX-R) in Subjects with Severe Hemophilia B.
Maureen D. Mayes, MS, Department of Defense, $928,125, Candidate Gene Polymorphisms in Scleroderma: Defining Genetic Susceptibility Factors.
Rade Paravina, Dental Branch (DB) and GSBS, Kuraray America Inc., $4,800, Polymerization- and Aging-Dependent Changes in Color of Resin Cements; Kuraray America Inc., $6,000, Effect of Accelerated Aging on Color, Translucency and Gloss Composites; and Kuraray America Inc., $4,000, Polymerization-Dependent Changes in Color and Translucency of Composites.
Bela Patel, MS, Encysive Pharmaceuticals, $2,750, ACCP Board Review Material for Fellows.
Sudhir Paul, MS and GSBS, NIH, $1,851,527, Nucleophilic Antibodies: Characterization and Induction.
J. Marc Rhoads, MS, The Gerber Foundation, $320,512, Effect of Lactobacillus Rhamnous GG on Colic Symptoms and Excessive Breath Hydrogen in Infants with Colic.
Kishore Shetty, DB and GSBS, Texas A&M Research Foundation, $9,072, TX/OK AIDS Education and Training Center, Local Performance Site.
Jeremy Daniel Slater, MS, Johnson & Johnson, $199,069, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study.
Patricia L. Starck, SON, Center for Houston’s Future, $9,000, Clinical Training Faculty Salary.
Angela L. Stotts, MS, UT Austin, $50,309, Add Res Type by YC 3.1.07 A Transtheroretical Model Group Therapy for Cocaine.
Patrick M. Tarwater, School of Public Health (SPH), University of Pittsburgh, $8,841, Semen in Transmission of HIV-Data Center.
Adel A. Wassef, MS, Forest Laboratories Inc., $150,600, A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia (RGH-MD-03).
Robert Joseph Yetman, MS, Medimmune Inc., $122,324, A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (Medi-524), A Humanized Enhanced Potency Monoclonal Antibody against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment.
Giuseppe N. Colasurdo, MS, Texas Department of State Health Services, $2,257,542, Women, Infants, and Children (Project #17-Cost Service Allocation Plan).
Alfred L. McAlister, SPH, Texas Department of State Health Services, $351,999, TDH Multi-Cultural Tobacco Prevention and Evaluation Studies.
Jerry S. Wolinsky, MS and GSBS, Clayton Foundation for Research, $69,256, Viral Mimicry and Multiple Sclerosis.
Ali J. Marian, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, Burroughs Wellcome Fund, $675,000, Molecular Genetics and Pathogenesis of Arrhythmogenic Right Ventricular Cardiomyopathy; and Greater Houston Community Foundation, $274,701, Genetic Determinants of Clinical Outcome in Patients with Cardiovascular Disease.
Previous story Next story